Skip to main content

Table 5 Secondary analysis: PD-L1

From: Neoadjuvant rituximab modulates the tumor immune environment in patients with high risk prostate cancer

PD-L1 density (mm2/mm2)

Rituximab

Mean (95% CI)

Controls

Mean (95% CI)

p

Tumor region

0.059 (0.018, 0.099)

0.083 (0.040, 0.127)

0.36

Non-neoplastic region

0.054 (0.004, 0.103)

0.132 (0.056, 0.321)

0.39

Within group difference

   

 Tumor − non-neoplastic

0.005 (− 0.012, + 0.022)

− 0.049 (− 0.248, + 0.151)

 0.56

  1. 1. Density of tumor for subjects treated with rituximab
  2. 2. Density of adjacent normal tissue for subjects treated with rituximab
  3. 3. Use one sample t test to get the mean and 95% CI
  4. 4. p value is from two sample t-test
  5. For two sample t-test, the Welch (or Satterthwaite) approximation to the degrees of freedom is used
  6. Null hypothesis is no difference
  7. 5. (Tumor − normal) is calculated by: column K − column L